A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

Table 2 Comparison of mean delta Ct values for each of the 16 genes in the 16 gene signature in discovery dataset patients pre-treatment and post-treatment. Expression of the genes in patients who developed grade 0–1 diarrhea are compared to patients who developed grade 2–4 diarrhea

Discovery Dataset
	Gene Expression Delta Ct Values Pre-Treatment Means			Gene Expression Delta Ct Values Post-Treatment Means
	Grade 0–1 Diarrhea Pre Treatment N = 129	Grade 2–4 Diarrhea Pre Treatment N = 21	Pre-Treatment Difference	Grade 0–1 Diarrhea Post Treatment N = 129	Grade 2–4 Diarrhea Post Treatment N = 21	Post Treatment Difference	Post Treatment Difference p value
Predictor Gene Name
CCR3	16.71	16.98	0.27	16.28	17.40	1.12	0.0001
CCL3	20.60	20.90	0.30	20.47	21.00	0.53	0.007
IL8	22.14	21.84	−0.30	22.47	23.13	0.65	0.014
IL5	23.08	23.20	0.12	22.74	23.42	0.67	0.017
GADD45A	19.86	20.05	0.19	19.62	19.28	−0.34	0.031
PTGS2	17.40	17.49	0.09	17.43	17.76	0.33	0.037
Enhancer Variable Gene Name
MMP9	14.29	14.41	0.11	14.20	13.69	−0.52	0.078
CARD12	17.63	17.73	0.09	17.54	17.25	−0.29	0.096
SOCS3	18.31	18.42	0.11	18.11	17.78	−0.33	0.114
F5	17.98	18.04	0.06	17.69	17.40	−0.29	0.120
TLR9	18.14	18.11	−0.03	18.01	18.14	0.14	0.270
FAM210B	15.21	15.32	0.11	15.35	15.58	0.23	0.325
IL18BP	17.55	17.42	−0.13	17.32	17.46	0.14	0.355
UBE2C	21.23	21.31	0.08	20.31	20.17	−0.14	0.358
CXCL1	19.80	19.87	0.07	19.95	20.09	0.14	0.381
IL2RA	19.04	18.84	−0.20	18.44	18.57	0.12	0.486